1Yasojma K, Schwab C, McGeer EG, et al. Complementcomponents, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol, 2001, 21 :1214-1219.
2Mathey D, Schafer J, Schafer HJ, et al. Early accumulation of the terminal complement-complex in ischaemic myocardium after reperfusion. Eur Heart J, 1994, 15: 418-423.
3Qin X, Goldfine A, Krumrei N, et al. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes.Diabetes, 2004, 53: 2653-2661.
4Acosta J, Qin X, Halperin J. Complement and complement regulatory proteins as potential molecular targets for vascular diseases. Current Pharmaceutical Design, 2004, 10 : 203-211.
5Vlaicu R, Rus HG, Niculescu F. Quantitative determinations of immunoglobulins and complement components in human aortic atherosclerotic wall. Med Interne, 1985, 23 : 29-35.
6Yasojma K, Schwab C, McGeer EG, et al. Generation of C-reactive protein and complement components in atherosclemtic plaques. Am J Pathol, 2001, 158: 1039-1051.
7Torzewski J, Torzewski M, Bowyer DE. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol, 1998, 1386-1392.
8Saadi S, Holzknecht RA, Patte CP, et al. Endothelial cell activation by pore forming structures: pivotal role for interleukin-1 alpha .Circulation, 2000, 101 : 1867-1873.
9Benzaquen LK, Nicholson-Weller A, Halperin JA, et al. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med,1994, 179: 985-992.
10Niculescu F, Badea T, Rus H. Sublytic C5b-9 induces proliferation of human aortic smooth muscle cells : role of mitogen activated protein kinase and phosphatidylinositol 3-kinase. Atherosclerosis, 1999,142 : 47-56.
